Abstracts tagged "corticosteroids"

Abstract Number: 1302 • 2015 ACR/ARHP Annual Meeting
Inflammation Signs on Magnetic Resonance Imaging in Chronic or Recurrent Gonarthritis Treated with Intra-Articular Infliximab or Corticosteroids
Gülsah Akdemir¹, Arie E. van der Bijl², Badelog J.E. de Lange-Brokaar³, T. W. J. Huizinga¹, Cornelia F. Allaart¹ and Margreet Kloppenburg³, ¹Rheumatology, LUMC, Leiden, Netherlands, ²Isala Klinieken, Zwolle, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: To evaluate synovial inflammation on magnetic resonance imaging (MRI) before treatment and changes after treatment with intra-articular (i.a.) infliximab (IFX) or methylprednisolone (MP) injections…
Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Brandon Arnieri¹, Khaled Sarsour¹, David Oliveri¹, Attila Pethö-Schramm², Avani Shah¹ and George Quartey¹, ¹Genentech, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…
Abstract Number: 1833 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
Maeve Gamble¹ and Janet E. Pope², ¹Medicine, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Osteoporosis (OP) and avascular necrosis (AVN) are well-recognized musculoskeletal complications of systemic lupus erythematosus (SLE) and cause morbidity. Steroid therapy and the underlying disease…
Abstract Number: 1979 • 2015 ACR/ARHP Annual Meeting
Baseline Data on Patients Enrolled in a Randomized, Double-Blind Trial of Tocilizumab in Giant Cell Arteritis
Katie Tuckwell¹, Neil Collinson¹, Micki Klearman², Sophie Dimonaco¹, John H. Stone³ and on behalf of the GiACTA Investigators, ¹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²Genentech, South San Francisco, CA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: GiACTA, a randomized, double-blind, placebo-controlled trial of the interleukin-6 receptor alpha inhibitor tocilizumab (TCZ) in patients (pts) with giant cell arteritis (GCA), is the…
Abstract Number: 1990 • 2015 ACR/ARHP Annual Meeting
Corticosteroid Use in Idiopathic Aortitis: A Systematic Review
Nancy Maltez¹ and Nataliya Milman², ¹Internal Medicine, University of Ottawa, Ottawa, ON, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Idiopathic aortitis (IA) is a poorly defined entity with no specific pathological or clinical criteria for its classification or diagnosis, except for the presence…
Abstract Number: 2537 • 2015 ACR/ARHP Annual Meeting
Prescription Medication Use in Sweden Among Pregnant Women with Systemic Lupus Erythematosus and General Population Comparators
Kristin Palmsten¹, Julia F Simard^2,3, Christina D Chambers^1,4 and Elizabeth V Arkema⁵, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁵Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: There is limited information regarding medication use patterns among pregnant women with systemic lupus erythematosus (SLE). We aimed to characterize trends of medications used…
Abstract Number: 3142 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Enhances Regulatory T-Cell Activation and Proliferation in Giant Cell Arteritis
Chie Miyabe¹, Klemen Strle², Yoshishige Miyabe¹, John H. Stone^1,3, Andrew D. Luster^1,4 and Sebastian Unizony^1,5, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Charlestown, MA, ⁵Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose : CD4+ T helper (Th) 17 cells, Th1 cells, and regulatory T-cells (Treg) contribute to the pathogenesis of giant cell arteritis (GCA). Interleukin (IL)-6,…
Abstract Number: 3144 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab for Polymyalgia Rheumatica
Lindsay Lally¹, Lindsy J. Forbess², Chris Hatzis¹ and Robert F. Spiera³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Rheumatology, HSS, New York, NY
Background/Purpose: IL-6 is a pivotal cytokine in PMR pathogenesis, yet the efficacy of IL-6 blockade with tocilizumab (TCZ) for treatment of PMR is unknown. The…
Abstract Number: 1235 • 2014 ACR/ARHP Annual Meeting
Recovery of Renal Function after Corticosteroid Therapy for IgG4-Related Kidney Disease
Takako Saeki¹, Mitsuhiro Kawano², Ichiro Mizushima², Motohisa Yamamoto³, Yoshifumi Ubara⁴, Hitoshi Nakashima⁵, Yoko Wada⁶, Tomoyuki Ito⁷, Hajime Yamazaki⁷, Ichiei Narita⁶ and Takao Saito^5,8, ¹Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, ²Kanazawa University Hospital, Kanazawa, Japan, ³Sapporo Medical University School of Medicine, Sapporo, Japan, ⁴Toranomon Hospital, Tokyo, Japan, ⁵Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, ⁶Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ⁷Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁸General Medical Research Center, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
Background/Purpose: In our earlier study of IgG4-related kidney disease (IgG4-RKD), we found that renal dysfunction, which was mostly attributable to IgG4-related tubulointerstitial nephritis, was significantly…
Abstract Number: 1114 • 2014 ACR/ARHP Annual Meeting
Clinical Effectiveness of Exercise and Corticosteroid Injection for Subacromial Impingement Syndrome: A Randomised Controlled Trial
Edward Roddy¹, Reuben Ogollah¹, Irena Zwierska¹, Praveen Datta², Alison Hall¹, Elaine Hay¹, Sue Jackson², Martyn Lewis¹, Julie Shufflebotham³, Kay Stevenson², Danielle van der Windt¹, Julie Young¹ and Nadine Foster¹, ¹Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ²University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom, ³Staffordshire and Stoke-on-Trent Partnership Trust, Stoke-on-Trent, United Kingdom
Background/Purpose: Subacromial impingement syndrome (SIS) is the most common cause of shoulder pain. It is commonly managed by exercise and corticosteroid injection yet how these…
Abstract Number: 1025 • 2014 ACR/ARHP Annual Meeting
Leptin Production By Osteoarthritis Synovial Fibroblasts: Stimulation By Glucocorticoids and Mineralocorticoids through the Glucocorticoid Receptor and GILZ (Glucocorticoid-Induced Leucine Zipper) Protein
Olivier Malaise¹, Biserka Relic¹, Sophie Neuville², Edith Charlier¹, Dominique de Seny¹ and Michel G. Malaise¹, ¹Department of Rheumatology, GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ²GIGA Research - University of Liège - CHU of Liège, Liège, Belgium
Background/Purpose: Osteoarthritis (OA) is a metabolic disorder for which leptin is playing a catabolic role on cartilage. In mice, obesity due to impaired leptin did…
Abstract Number: 803 • 2014 ACR/ARHP Annual Meeting
Corticosteroid-Related Adverse Events in Patients with Giant Cell Arteritis: A Claims-Based Analysis
Gordon H. Sun¹, Khaled Sarsour², Eunice Chang¹, Michael S. Broder¹, Neil Collinson³, Katie Tuckwell³, Pavel Napalkov² and Micki Klearman², ¹Partnership for Health Analytic Research, LLC, Beverly Hills, CA, ²Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ³Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose Giant cell arteritis (GCA) is an inflammatory vasculitis preferentially affecting large and medium-sized arteries with an incidence of 1 to 30/100,000. High-dose oral corticosteroids…
Abstract Number: 492 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept
J. Carter Thorne¹, Edward C. Keystone², Janet E. Pope³, Melanie Poulin-Costello⁴, Krystene Phan-Chronis⁵ and Boulos Haraoui⁶, ¹Southlake Regional Health Centre, Newmarket, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³St Joseph Health Care, London, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The Canadian Methotrexate and Etanercept Outcome Study (CAMEO) evaluated etanercept (ETN) monotherapy vs ETN plus methotrexate (MTX) in biologic-naïve patients with rheumatoid arthritis…
Abstract Number: 295 • 2014 ACR/ARHP Annual Meeting
Intra-Articular Corticosteroid Injections in Juvenile Idiopathic Arthritis: Results from a UK Prospective Collaborative Study
Eileen Baildam¹, Roberto Carrasco², Susannah Holt³, Helen Foster⁴, Lucy R. Wedderburn⁵, Alice Chieng⁶, Joyce Davidson⁷, Yiannis Ioannou⁸, Kimme L. Hyrich⁹ and Wendy Thomson¹⁰, ¹Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Paediatric Palliative Care, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁴Newcastle University Medical School, Professor of Paediatric Rheumatology, Newcastle Upon Tyne, United Kingdom, ⁵Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁶Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁷Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁸Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹⁰Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
Background/Purpose Intra-articular corticosteroid injections (IACI) are a standard treatment in juvenile idiopathic arthritis (JIA). This study assessed response to IACI in a large prospective cohort…
Abstract Number: 240 • 2014 ACR/ARHP Annual Meeting
An Observational Study on the Influence of Glucocorticoid Exposure on Bone
Joseph Heath¹, Alexander Oldroyd², Maarten Boers³ and Marwan Bukhari², ¹Faculty of health and medicine, Lancaster University, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Dep of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose It is well known that glucocorticoids are detrimental to bone health and has been postulated that their influence is more than their effect on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].